Abstract
A sequential therapy of caspofungin (CAS) and fluconazole (FLC) administration for treatment of Candida albicans infection was investigated. Treatment with CAS followed by FLC was as effective as CAS treatment given alone for the same duration. Our data suggest that switching from CAS to FLC is a potentially explorable therapeutic option for treatment of systemic candidiasis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / pharmacology
-
Antifungal Agents / therapeutic use*
-
Candida albicans / drug effects
-
Candidiasis / drug therapy*
-
Candidiasis / microbiology
-
Caspofungin
-
Colony Count, Microbial
-
Drug Therapy, Combination
-
Echinocandins
-
Fluconazole / administration & dosage
-
Fluconazole / pharmacology
-
Fluconazole / therapeutic use*
-
Humans
-
Kidney / microbiology
-
Lipopeptides
-
Male
-
Mice
-
Peptides, Cyclic / administration & dosage
-
Peptides, Cyclic / pharmacology
-
Peptides, Cyclic / therapeutic use*
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Peptides, Cyclic
-
Fluconazole
-
Caspofungin